Innovation at the intersection of AI and immunology is accelerating personalized cancer treatment. New computational tools like BATMAN outperform existing models in predicting T cell receptor cross-reactivity, reducing off-target risks. Parallel work from the Baker lab harnesses AI to design bespoke protein binders targeting peptide-MHC complexes, enabling scalable immunotherapies against elusive cancer epitopes. These breakthroughs mark a step-change in precision immunotherapy, suggesting enhanced targeting specificity and therapy customization may soon be more systematic and rapid.